BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)

Summary

The main objective of this study is to assess the safety, tolerability and pharmacokinetics of orally administered BI 705564 in patients with systemic lupus erythematosus

Timeline

Start

2019-03-16

Primary completion

2019-12-21

Completion

2020-01-07

Outcome

Outcome not reported

Stopped (Business): “Based on a strategic decision, the application for the trial has been withdrawn before initiation.”

Drugs

Indications